BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
| Revenue (TTM) | $713.07M |
| Gross Profit (TTM) | $673.41M |
| EBITDA | $-472.75M |
| Operating Margin | -43.90% |
| Return on Equity | -1790.00% |
| Return on Assets | -26.00% |
| Revenue/Share (TTM) | $3.67 |
| Book Value | $-12.88 |
| Price-to-Book | 123.68 |
| Price-to-Sales (TTM) | 17.98 |
| EV/Revenue | 20.5 |
| EV/EBITDA | -9.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 120.40% |
| Shares Outstanding | $195.49M |
| Float | $167.19M |
| % Insiders | 3.91% |
| % Institutions | 99.69% |
Volatility is currently expanding
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis
PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.
BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BridgeBio pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook.
BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock?
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events
PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026.
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BBIO and any ticker you trade — then tracks every position and per-strategy win rate.
